Table 1.
List of FDA approved therapy to treat advanced renal cell carcinoma patients.
| Target | Therapy | Citations |
|---|---|---|
| VEGFR | Sorafenib | [113] |
| Sunitinib | [112,182] | |
| Pazopanib | [183] | |
| Cabozantinib | [184] | |
| Axitinib | [185,186] | |
| VEGFR + mTOR | Lenvatinib + Everolimus (anti-mTOR) | [187] |
| VEGF | Bevacizumab + IFN-α (Cytokine) | [188,189] |
| mTOR | Temsirolimus | [190] |
| Everolimus | [191] | |
| PD-1 | Nivolumab | [197,198,199] |
| Pembrolizumab | [200,201,202] | |
| PD-1 + CTLA-4 | Nivolumab + Ipilimumab (anti-CTLA-4) | [210,211,232] |
| PD-1 + VEGFR | Nivolumab + Cabozantinib (anti-VEGFR) | [212,213,214,215] |
| Pembrolizumab + Axitinib (anti-VEGFR) | [216,217,218] | |
| Pembrolizumab + Lenvatinib (anti-VEGFR) | [219] | |
| PD-L1 + VEGFR | Avelumab + Axitinib (anti-VEGFR) | [203,204] |
| HIF-2α | Belzutifan | [192] |